Multimorbidity and COPD medication receipt among medicaid beneficiaries with newly diagnosed COPD

Respiratory Care

Volumn 60, Issue 11, 2015, Pages 1592-1602

  Ajmera, Mayank ^a   Sambamoorthi, Usha ^b   Metzger, Aaron ^c   Dwibedi, Nilanjana ^b   Rust, George ^d   Tworek, Cindy ^b  

^a RTI HEALTH SOLUTIONS   (United States)

^b Department of Pharmaceutical Systems and Policy ^*  (United States)

^c WEST VIRGINIA UNIVERSITY   (United States)

^d MOREHOUSE SCHOOL OF MEDICINE   (United States)

Author keywords

COPD; Medicaid; Medication management; Multimorbidity

Indexed keywords

ANTHROPOMETRY; ANXIETY; ARTICLE; BRONCHIECTASIS; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSPNEA; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LONGITUDINAL STUDY; LUNG FUNCTION TEST; MORBIDITY; MULTIMORBIDITY; OSTEOPOROSIS; RETROSPECTIVE STUDY; SCHIZOPHRENIA; STATISTICAL ANALYSIS; ADULT; ARTHRITIS; CARDIOVASCULAR DISEASES; COMORBIDITY; DRUG UTILIZATION; FEMALE; HYPERLIPIDEMIAS; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; MEDICAID; MENTAL DISORDERS; MIDDLE AGED; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; STATISTICS AND NUMERICAL DATA; UNITED STATES;

BRONCHODILATING AGENT; CORTICOSTEROID;

ADRENAL CORTEX HORMONES; ADULT; ARTHRITIS; BRONCHODILATOR AGENTS; CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS; DRUG UTILIZATION; FEMALE; HUMANS; HYPERLIPIDEMIAS; INTERNATIONAL CLASSIFICATION OF DISEASES; LONGITUDINAL STUDIES; MALE; MEDICAID; MENTAL DISORDERS; MIDDLE AGED; OSTEOPOROSIS; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84944748559     PISSN: 00201324     EISSN: 19433654     Source Type: Journal    
DOI: 10.4187/respcare.03788     Document Type: Article

References (38)

1. Boyd CM, Ritchie CS, Tipton EF, Studenski SA, Wieland D. From bedside to bench: summary from the American Geriatrics Society /National Institute on Aging research conference on comorbidity and multiple morbidity in older adults. Aging Clin Exp Res 2008;20(3): 181-188.
2. Fortin M, Soubhi H, Hudon C, Bayliss EA, van den Akker M. Multimorbidity’s many challenges. BMJ 2007;334(7602):1016-1017.
3. Valderas JM, Starfield B, Sibbald B, Salisbury C, Roland M. De-fining comorbidity: implications for understanding health and health services. Ann Fam Med 2009;7(4):357-363.
4. van den Akker M, Buntinx F, Knottnerus JA. Comorbidity or multimorbidity what’s in a name? A review of literature. Eur J Gen Pract 1996;2(2):65-70.
5. Agency for Healthcare Research and Quality. Optimizing prevention and healthcare management for the complex patient. Updated 2007. http://archive.ahrq.gov/fund/trans101507.htm. Accessed June 10, 2014.
6. Marengoni A, Angleman S, Melis R, Mangialasche F, Karp A, Garmen A, et al. Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev 2011;10(4):430-439.
7. Naessens JM, Stroebel RJ, Finnie DM, Shah ND, Wagie AE, Litchy WJ, et al. Effect of multiple chronic conditions among working-age adults. Am J Manag Care 2011;17(2):118-122.
8. Taylor AW, Price K, Gill TK, Adams R, Pilkington R, Carrangis N, et al. Multimorbidity—not just an older person’s issue. Results from an Australian biomedical study. BMC Public Health 2010;10:718-718.
9. Schnell K, Weiss CO, Lee T, Krishnan JA, Leff B, Wolff JL, Boyd C. The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from NHANES 1999-2008. BMC Pulm Med 2012;12:26.
10. Global Initiative for Chronic Lung Diseases. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2014. http://www.goldcopd.org/guidelinesglobal-strategy-for-diagnosis-management.html. Accessed August 10, 2014.
11. Han MK. Update in chronic obstructive pulmonary disease in 2010. Am J Respir Crit Care Med 2011;183(10):1311-1315.
12. Tsiligianni IG, Kosmas E, Van der Molen T, Tzanakis N. Managing comorbidity in COPD: a difficult task. Curr Drug Targets 2013; 14(2):158-176.
13. van der Woude HJ, Zaagsma J, Postma DS, Winter TH, van Hulst M, Aalbers R. Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers. Chest 2005;127(3):818-824.
14. Caughey GE, Preiss AK, Vitry AI, Gilbert AL, Roughead EE. Co-morbid diabetes and COPD: impact of corticosteroid use on diabetes complications. Diabetes Care 2013;36(10):3009-3014
15. Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med 2010;123(11):1001-1006.
16. Ogawa R, Stachnik JM, Echizen H. Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 1, drugs administered intravenously). Clin Pharmacokinet 2013;52(3):169-185.
17. Kaiser Family Foundation. Medicaid matters: understanding Medicaid’s role in our health care system. Publication 8165. Updated 2011. https://kaiserfamilyfoundation.files.wordpress.com/2013/01/8165.pdf. Accessed August 17, 2014.
18. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 2012; 380(9836):37-43.
19. Savva, G. Multimorbidity in the older population. http://www.thehealthwell.info/node/111238. Accessed August 10, 2014.
20. Dalal AA, Shah M, D’Souza AO, Chaudhari S, Crater G. Clinical and economic outcomes for patients initiating fluticasone propionate/salmeterol combination therapy (250/50 mcg) versus anticholinergics in a comorbid COPD/depression population. Int J Chron Obstruct Pulmon Dis 2012;7:11-19.
21. Halpern R, Baker CL, Su J, Woodruff KB, Paulose-Ram R, Porter V, Shah H. Outcomes associated with initiation of tiotropium or fluticasone/salmeterol in patients with chronic obstructive pulmonary disease. Patient Prefer Adherence 2011;5:375-388.
22. Cooke CR, Joo MJ, Anderson SM, Lee TA, Udris EM, Johnson E, Au DH. The validity of using ICD-9 codes and pharmacy records to identify patients with chronic obstructive pulmonary disease. BMC Health Serv Res 2011;11:37.
23. Gershon AS, Wang C, Guan J, Vasilevska-Ristovska J, Cicutto L, To T. Identifying patients with physician diagnosed COPD in health administrative databases. COPD 2009;6(5):388-394.
24. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive sum- mary. Am J Respir Crit Care Med 2007;176(6):532-555.
25. Fabbri LM, Luppi F, Beghé B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J 2008;31(1):204-212.
26. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009;33(5):1165-1185.
27. Nussbaumer-Ochsner Y, Rabe KF. Systemic manifestations of COPD. Chest 2011;139(1):165-173.
28. Goodman RA, Posner SF, Huang ES, Parekh AK, Koh HK. Defining and measuring chronic conditions: imperatives for research, policy, program, and practice. Prev Chronic Dis 2013;10:120239.
29. Andersen RM. Revisiting the behavioral model and access to medical care: does it matter? J Health Soc Behav 1995;36(1):1-10.
30. Babitsch B, Gohl D, von Lengerke T. Re-revisiting Andersen’s behavioral model of health services use: a systematic review of studies from 1998-2011. Psychosoc Med 2012;9:Doc11.
31. Lin PJ, Shaya FT, Scharf SM. Economic implications of comorbid conditions among Medicaid beneficiaries with COPD. Respir Med 2010;104(5):697-704.
32. Au DH, Udris EM, Curtis JR, McDonell MB, Fihn SD, ACQUIP Investigators. Association between chronic heart failure and inhaled beta-2-adrenoceptor agonists. Am Heart J 2004;148(5):915-920.
33. Lemaitre RN, Siscovick DS, Psaty BM, Pearce RM, Raghunathan TE, Whitsel EA, et al. Inhaled beta-2 adrenergic receptor agonists and primary cardiac arrest. Am J Med 2002;113(9):711-716.
34. Macie C, Wooldrage K, Manfreda J, Anthonisen N. Cardiovascular morbidity and the use of inhaled bronchodilators. Int J Chron Obstruct Pulmon Dis 2008;3(1):163-169.
35. Martin RM, Dunn NR, Freemantle SN, Mann RD. Risk of non-fatal cardiac failure and ischaemic heart disease with long acting beta 2 agonists. Thorax 1998;53(7):558-562.
36. Slatore CG, Bryson CL, Au DH. The association of inhaled corticosteroid use with serum glucose concentration in a large cohort. Am J Med 2009;122(5):472-478.
37. Ansari S, Hosseinzadeh H, Dennis S, Zwar N. Patients’ perspectives on the impact of a new COPD diagnosis in the face of multimorbidity: a qualitative study. NPJ Prim Care Respir Med 2014;24:14036.
38. Noyes K, Liu H, Lyness JM, Friedman B. Medicare beneficiaries with depression: comparing diagnoses in claims data with the results of screening. Psychiatr Serv 2011;62(10):1159-1166.